Zealand Pharma AS ZEAL
News
Zealand Pharma announces positive topline results from 13-week Phase 1b multiple ascending dose clinical trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
Zealand Pharma Announces Financial Results for the First Half of 2024
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
Zealand Pharma Appoints Eric Cox as Chief Commercial Officer
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
Zealand Pharma shares surge after positive results of weight-loss drug that could contend with GLP-1s